Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chloroquine + A-CQ is a combination drug consisting of chloroquine and a second component referred to as "A-CQ." Chloroquine is a 4-aminoquinoline antimalarial agent that works by increasing the levels of heme in the blood, which is toxic to malaria parasites, thereby killing them and stopping infection. It also has activity against amebiasis outside the intestines and has been used for rheumatoid arthritis and lupus erythematosus. The mechanism of action for "A-CQ" cannot be determined from available sources; it may refer to an analog or derivative of chloroquine, but no definitive information on this specific entity was found in current literature or databases[1][2][4]. Therefore, this combination should be considered as containing at least one well-characterized antimalarial small molecule (chloroquine), with incomplete information about the second component.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chloroquine + A-CQ.